The Lasker Foundation has awarded its 2026 Basic Medical Research Prize — one of the most prestigious honors in science, often called "America's Nobel" — to two sleep researchers whose work, done independently and nearly simultaneously more than 25 years ago, revealed the biological cause of narcolepsy and opened an entirely new field of sleep medicine.
Emmanuel Mignot, director of the Center for Narcolepsy at Stanford University School of Medicine, and Masashi Yanagisawa, of the University of Tsukuba in Japan, are being recognized for identifying orexin (also called hypocretin), a peptide produced by a small cluster of neurons in the hypothalamus, and for showing that its loss is what causes narcolepsy's uncontrollable sleep attacks.
Two Paths to the Same Discovery
Yanagisawa's team found orexin in the late 1990s while searching for previously unknown signaling molecules in the brain. They initially suspected the peptide was involved in feeding behavior, since injecting it into rodents increased food intake. But further experiments revealed its more important role: orexin-producing neurons keep the brain in a stable, alert waking state, and silencing them plunges animals into sleep almost instantly.
Around the same time, Mignot was pursuing a different line of evidence — a colony of narcoleptic dogs at Stanford that inherited the condition through a single mutated gene. His group traced the mutation to the receptor that orexin binds to, showing that these dogs' brains simply couldn't respond to the wakefulness-promoting signal. Mignot's team then found that in humans with narcolepsy, the orexin-producing neurons themselves are destroyed, likely by an autoimmune process, leaving the brain unable to sustain consistent alertness.
Together, the two lines of research established that orexin functions as the brain's stability switch for wakefulness, and that narcolepsy type 1 — marked by excessive daytime sleepiness and sudden muscle weakness called cataplexy — is fundamentally an orexin-deficiency disease.
From Basic Science to a New Drug Class
The practical payoff of that discovery has arrived only recently. For decades, narcolepsy treatment relied on stimulants and other medications that managed symptoms without addressing the missing signal itself. That changed this year with the FDA's August 2026 approval of oveporexton (brand name Orzeyful), the first drug designed to directly replace orexin's function in the brain by activating the same receptors Mignot's dog studies first implicated.
In Phase 3 trials, oveporexton produced significant improvements in wakefulness and cut cataplexy attacks in patients with narcolepsy type 1, results researchers describe as a categorical shift from managing symptoms to correcting the underlying deficiency. Several additional orexin-targeting compounds are now in development for narcolepsy type 2 and other disorders of wakefulness, all tracing their scientific lineage directly back to the discoveries being honored this year.
The Lasker Award has a strong track record of anticipating future Nobel Prizes; more than 90 Lasker laureates have gone on to win a Nobel. Whether or not that pattern repeats here, the award formalizes what sleep specialists have said for years: the orexin discovery ranks among the most consequential findings in the field's history, because it gave narcolepsy — long a poorly understood and frequently misdiagnosed condition — a clear, testable, and ultimately treatable biological mechanism.
What This Means for Patients
For the estimated 1 in 2,000 Americans living with narcolepsy, the practical significance of this award is that the underlying science behind their diagnosis is now well enough understood to build precise treatments around it, rather than working around the disorder with stimulants alone. Patients newly diagnosed with narcolepsy type 1 can now discuss orexin-receptor agonist therapy with their sleep specialist as a treatment that targets the actual cause of their symptoms. The recognition also signals to researchers and drugmakers that continued investment in orexin biology — including for narcolepsy type 2, idiopathic hypersomnia, and possibly insomnia — is likely to keep paying off, meaning more targeted options are probably still to come.
